A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 60,877 shares of GILD stock, worth $5.4 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
60,877
Previous 72,454 15.98%
Holding current value
$5.4 Million
Previous $4.97 Million 2.64%
% of portfolio
0.03%
Previous 0.03%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$66.59 - $83.99 $770,912 - $972,352
-11,577 Reduced 15.98%
60,877 $5.1 Million
Q2 2024

Aug 14, 2024

SELL
$63.15 - $72.88 $471,351 - $543,976
-7,464 Reduced 9.34%
72,454 $4.97 Million
Q1 2024

May 15, 2024

BUY
$71.58 - $87.29 $5.72 Million - $6.98 Million
79,918 New
79,918 $6.09 Billion
Q4 2023

Aug 14, 2024

BUY
$73.27 - $83.09 $844,876 - $958,110
11,531 Added 40.62%
39,919 $3.23 Billion
Q3 2023

Aug 14, 2024

SELL
$73.94 - $80.67 $207,697 - $226,602
-2,809 Reduced 9.0%
28,388 $2.13 Billion
Q2 2023

Aug 14, 2024

BUY
$76.01 - $86.7 $697,011 - $795,039
9,170 Added 41.63%
31,197 $2.4 Billion
Q1 2023

Aug 14, 2024

SELL
$77.31 - $88.08 $2.55 Million - $2.9 Million
-32,945 Reduced 59.93%
22,027 $1.83 Billion
Q4 2022

Aug 14, 2024

SELL
$62.32 - $89.47 $937,043 - $1.35 Million
-15,036 Reduced 21.48%
54,972 $4.72 Billion
Q3 2022

Aug 14, 2024

BUY
$59.54 - $68.01 $1.04 Million - $1.19 Million
17,534 Added 33.41%
70,008 $4.32 Billion
Q2 2022

Aug 14, 2024

BUY
$57.72 - $65.01 $283,174 - $318,939
4,906 Added 10.31%
52,474 $3.24 Billion
Q1 2022

Aug 14, 2024

SELL
$57.92 - $72.58 $1.44 Million - $1.81 Million
-24,886 Reduced 34.35%
47,568 $2.83 Billion
Q4 2021

Aug 30, 2024

BUY
$64.88 - $73.64 $1.81 Million - $2.05 Million
27,842 Added 184.59%
42,925 $3.12 Billion
Q3 2021

Aug 30, 2024

SELL
$67.69 - $73.03 $84,003 - $90,630
-1,241 Reduced 7.6%
15,083 $1.05 Billion
Q2 2021

Aug 30, 2024

SELL
$63.47 - $69.35 $3.56 Million - $3.89 Million
-56,130 Reduced 77.47%
16,324 $1.12 Billion
Q1 2021

Aug 30, 2024

SELL
$60.0 - $68.46 $5.31 Million - $6.06 Million
-88,476 Reduced 43.8%
113,501 $7.34 Billion
Q4 2020

Aug 30, 2024

BUY
$56.65 - $64.55 $1.26 Million - $1.43 Million
22,159 Added 12.32%
201,977 $11.8 Billion
Q3 2020

Aug 30, 2024

BUY
$62.1 - $78.08 $10.5 Million - $13.2 Million
168,698 Added 1517.07%
179,818 $11.4 Billion
Q2 2020

Aug 30, 2024

SELL
$72.34 - $84.0 $29,153 - $33,852
-403 Reduced 3.5%
11,120 $856 Million
Q1 2020

Aug 30, 2024

SELL
$62.63 - $80.22 $1.73 Million - $2.22 Million
-27,625 Reduced 70.57%
11,523 $861 Million
Q4 2019

Aug 30, 2024

SELL
$61.62 - $67.78 $228,425 - $251,260
-3,707 Reduced 8.65%
39,148 $2.54 Billion
Q3 2019

Aug 30, 2024

SELL
$62.51 - $69.0 $56,008 - $61,824
-896 Reduced 2.05%
42,855 $2.72 Billion
Q2 2019

Aug 30, 2024

SELL
$61.87 - $69.38 $447,753 - $502,103
-7,237 Reduced 14.19%
43,751 $2.96 Billion
Q1 2019

Aug 30, 2024

BUY
$62.53 - $70.05 $17,508 - $19,614
280 Added 0.55%
50,988 $3.31 Billion
Q4 2018

Aug 30, 2024

SELL
$60.54 - $79.0 $1.32 Million - $1.72 Million
-21,746 Reduced 30.01%
50,708 $3.17 Billion
Q3 2018

Aug 30, 2024

SELL
$71.28 - $78.92 $3.76 Million - $4.16 Million
-52,745 Reduced 41.93%
73,037 $5.64 Billion
Q2 2018

Aug 30, 2024

BUY
$64.88 - $75.68 $4.83 Million - $5.63 Million
74,380 Added 144.7%
125,782 $8.92 Billion
Q1 2018

Aug 30, 2024

SELL
$72.84 - $88.8 $1.18 Million - $1.44 Million
-16,164 Reduced 23.92%
51,402 $3.88 Billion
Q4 2017

Aug 30, 2024

SELL
$71.15 - $83.52 $38,990 - $45,768
-548 Reduced 0.8%
67,566 $4.84 Billion
Q3 2017

Aug 30, 2024

SELL
$72.11 - $85.47 $599,594 - $710,683
-8,315 Reduced 10.88%
68,114 $5.52 Billion
Q2 2017

Aug 30, 2024

SELL
N/A
-15,587 Reduced 16.94%
76,429 $5.41 Billion
Q1 2017

Aug 30, 2024

BUY
N/A
19,562
92,016 $6.25 Billion

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $111B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Federation Des Caisses Desjardins Du Quebec Portfolio

Follow Federation Des Caisses Desjardins Du Quebec and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.